Edition:
United States

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

7.99USD
2:02pm EDT
Change (% chg)

$-0.10 (-1.24%)
Prev Close
$8.09
Open
$8.08
Day's High
$8.09
Day's Low
$7.94
Volume
3,219
Avg. Vol
25,569
52-wk High
$13.68
52-wk Low
$5.28

Chart for

About

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid... (more)

Overall

Beta: --
Market Cap(Mil.): $199.20
Shares Outstanding(Mil.): 24.62
Dividend: --
Yield (%): --

Financials

  OVID.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -2.76 -- --
ROI: -59.79 -5.87 13.17
ROE: -59.79 -7.71 15.15

BRIEF-Ovid Therapeutics Reports Q1 Loss Per Share Of $0.54

* OVID THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE PROGRESS

May 08 2018

BRIEF-Ovid Therapeutics Reports Q4 Loss Per Share $0.45

* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS

Mar 29 2018

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF FRAGILE X SYNDROME

Mar 15 2018

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

Dec 20 2017

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME

Dec 19 2017

Earnings vs. Estimates